Gabelli Funds LLC Sells 15,800 Shares of Elevance Health, Inc. $ELV

Gabelli Funds LLC lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 56.4% in the 4th quarter, HoldingsChannel reports. The firm owned 12,200 shares of the company’s stock after selling 15,800 shares during the quarter. Gabelli Funds LLC’s holdings in Elevance Health were worth $4,277,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ELV. Physician Wealth Advisors Inc. raised its holdings in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares in the last quarter. Activest Wealth Management raised its holdings in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC raised its holdings in shares of Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after purchasing an additional 44 shares in the last quarter. ORG Partners LLC raised its holdings in shares of Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Elevance Health in the 4th quarter valued at about $38,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 1.8%

NYSE ELV opened at $389.17 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $84.51 billion, a PE ratio of 16.55, a price-to-earnings-growth ratio of 2.24 and a beta of 0.66. The company has a 50 day moving average price of $331.71 and a 200 day moving average price of $335.84. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $408.00.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts forecast that Elevance Health, Inc. will post 26.94 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ELV shares. Citigroup upgraded shares of Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Guggenheim boosted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and boosted their price target for the company from $363.00 to $498.00 in a report on Wednesday. The Goldman Sachs Group boosted their price target on shares of Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Finally, Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $396.16.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.